article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

Prescription and over-the-counter (OTC) medications originate in factories all over the world, moving into the American marketplace through supply chains that can involve numerous processing plants, manufacturers, suppliers, brokers, packagers, and distributors. Can patients really be confident in pharma supply chains?

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. In-house manufacturing the norm.

Insulin 328
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.

article thumbnail

Five Trends in Contract Drug Manufacturing Organisations

Pharmaceutical Technology

Avéma, for example, specialises in small molecule, oral solid, and liquid dose drugs. generic drugs at both small development companies and multinational pharmaceutical companies. This unique pedigree gives the company a foundational understanding of how to launch products at every stage of development.

article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

During the pandemic, the shortage of basic drugs such as paracetamol in key EU countries led to growing calls to push local drug manufacturing to ensure a smooth supply and to minimise shortages. Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues.